Loading
Dyne Therapeutics, Inc. Stock: price and insider trades · United States
1 insider bought €36k of shares over the last 90 days, the latest filed 06 Oct 2026.
Dyne Therapeutics, Inc.: what insiders have been doing
Dyne Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 16 insiders published 156 filings.
Both sides are active: 8 purchases worth €243k and 105 sales worth €114.6M, from 1 insider and 6 insiders respectively. The totals do not cover 25 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a sale of €29.5M from Rhodes Jason P, disclosed on 17 August 2026, or 1.1% of market capitalisation. Among those who bought: 1 senior executive.
With 156 filings in twelve months, the company is more active than the median of 19 filings across the 5,811 companies we follow on the same exchange. The full history, which starts in 2021, counts 12 purchases against 230 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -446.2 m USD.
The most recent open-market purchase was published on 6 October 2026, 12 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
358
Thresholds
n/a
Buy Volume
€15M
12 ops. · all time
Sell Volume
€161M
230 ops. · all time
Who traded when
BuySaleJason P. Rhodes68 sales
Kersten Dirk18 sales
Cox John1 buy9 sales
Johanna Friedl-Naderer10 sales
Kerr Douglas10 sales
Brian S. Posner8 buys
+3 other insiders
Since the insiders bought
- -13.5%Entry US$17.67 · Close 15 Oct 2026 US$15.29
- +143.5%Entry US$9.33 · Close at T+365 US$22.72
- -8.4%Entry US$16.69 · Close at T+365 US$15.29
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Dyne Therapeutics, Inc. Strong Buy (bullish), based on 15 analysts. Average price target: US$35.73.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$15.29
Analyst consensus
15 analystsStrong buy
US$10.00Target US$35.73(+134%)US$50.00
Income statement
EBITDA-US$438M
Net income-US$446.2M0.0% margin
Valuation
PER (forward)-4.6x
P/Book3.6x
Beta1.12
Balance sheet & cash
Market capUS$2.9B
Total debtUS$169.2M
Free Cash Flow-US$423.9M
Debt / Equity33%
Profitability & ownership
ROE-81.6%
ROA-39.0%
% insiders0.2%
% institutions103.7%
Last declaration on 6 October 2026
Declarations358 total
2,500 shares@ US$16.000.0014% mcap14.6% of flowCommon StockSEC:0001193125-26-415584:0
Canonical exit: 31 Dec 2026 (T+90)
35 shares@ US$18.88570.0000% mcap0.1% of flowCommon StockSEC144:0001972481-26-000279
3,745 shares@ US$24.350.0029% mcap18.7% of flowCommon StockSEC:0001814189-26-000005:0
1,290 shares@ US$18.880.0008% mcap5.0% of flowCommon StockSEC:0001814189-26-000005:1
900 shares@ US$24.350.0007% mcap38.9% of flowCommon StockSEC:0001915598-26-000005:0
185 shares@ US$18.880.0001% mcap6.2% of flowCommon StockSEC:0001915598-26-000005:1
5,000 shares@ US$24.3490.0039% mcap25.0% of flowCommon StockSEC144:0001972481-26-000278
268,354 shares@ US$26.200.23% mcap4.7% of flowCommon StockSEC:0001577014-26-000016:0
94,415 shares@ US$26.200.079% mcap1.6% of flowCommon StockSEC:0001577014-26-000016:1
63,643 shares@ US$26.200.053% mcap1.1% of flowCommon StockSEC:0001577014-26-000016:2
1,359,674 shares@ US$25.001.09% mcap22.6% of flowCommon StockSEC:0001577014-26-000016:3
478,377 shares@ US$25.000.38% mcap7.9% of flowCommon StockSEC:0001577014-26-000016:4
322,465 shares@ US$25.000.26% mcap5.4% of flowCommon StockSEC:0001577014-26-000016:5
1,797 shares@ US$26.280.0015% mcap17.1% of flowCommon StockSEC:0001697616-26-000002:0
1,556 shares@ US$26.280.0013% mcap8.5% of flowCommon StockSEC:0001814189-26-000004:0
226 shares@ US$26.280.0002% mcap10.6% of flowCommon StockSEC:0001915598-26-000004:0
1,359,674 shares@ US$25.961.13% mcap58.5% of flowCommonSEC144:0001628280-26-057190
322,465 shares@ US$25.960.27% mcap48.8% of flowCommonSEC144:0001628280-26-057191
478,377 shares@ US$25.960.40% mcap51.9% of flowCommonSEC144:0001628280-26-057188
268,354 shares@ US$26.170.22% mcap11.7% of flowCommonSEC144:0001628280-26-056843
63,643 shares@ US$26.170.053% mcap9.7% of flowCommonSEC144:0001628280-26-056842
94,415 shares@ US$26.170.079% mcap10.3% of flowCommonSEC144:0001628280-26-056844
25 of 358 declarations
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (ticker: DYN) is a U.S.-listed biotechnology company traded on the Nasdaq market in the United States. The company is focused on developing innovative therapies for genetically driven neuromuscular diseases, with a stated goal of delivering functional improvement for patients rather than only symptomatic relief. Dyne is headquartered in Waltham, Massachusetts, and was incorporated in Delaware in December 2017; it launched publicly in 2019. For investors, Dyne should be viewed as a clinical-stage biotech with substantial research intensity and a valuation narrative that depends heavily on clinical readouts, regulatory milestones, and the performance of its delivery technology platform. ([investors.dyne-tx.com](https://investors.dyne-tx.com/static-files/362949fc-b23f-4b1c-a7c6-b53089da850b?utm_source=openai))
At the center of the company’s strategy is the proprietary FORCE™ platform, which is designed to overcome the long-standing challenge of delivering oligonucleotide-based payloads into skeletal, cardiac, and smooth muscle, and more recently into the central nervous system. The platform is intended to address the underlying biology of rare diseases rather than simply manage symptoms. Dyne is building a portfolio of targeted therapies across Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease, with both clinical and preclinical programs. This makes the company a platform-driven developer rather than a single-asset story, although its near-term investor thesis remains concentrated around its lead clinical candidates. ([investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-preclinical-data-demonstrating-forcetm?utm_source=openai))
Read moreShow less
Competitively, Dyne operates in a demanding niche where targeted delivery, tissue selectivity, and safety are critical differentiators. Its positioning is based on the potential to solve a historically difficult drug-delivery problem in muscle disease. In DMD, Dyne has reported positive phase 1/2 data for DYNE-251, also referred to as z-rostudirsen, and management has signaled the potential for an accelerated regulatory filing in 2026. In DM1, DYNE-101 has received favorable regulatory recognition, including Fast Track and Breakthrough Therapy designations, which improves visibility for the program and supports the broader platform story. ([investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-positive-topline-results-phase-12/?utm_source=openai))
Recent corporate and clinical news has reinforced Dyne’s status as a catalyst-rich biotech. In 2025, the company released encouraging long-term clinical data in DMD and later reported positive topline results for z-rostudirsen, while indicating a path toward an accelerated submission in 2026. Dyne also disclosed progress in DYNE-101 for DM1, orphan-drug recognition in Europe for DYNE-251, and leadership additions intended to strengthen business development and scientific execution. In March 2026, the company reported its fourth-quarter and full-year 2025 results and recent business highlights. Overall, Dyne remains a speculative but potentially significant Nasdaq biotech name in the United States, with multiple clinical inflection points ahead and an emerging commercial narrative if development continues to progress. ([investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-long-term-clinical-data-phase-12/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
